MEDVi vs Noom Med: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

MEDVi beats Noom Med overall, scoring 7.7/10 vs 7.4/10. Noom Med is more affordable at $99/mo vs $299/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Noom Med for users who want a tiered entry into glp-1 care — from $99/mo .

A side-by-side comparison of MEDVi and Noom Med covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

MEDVi

#22 of 48

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Noom Med

#28 of 48

7.4/10

Noom restructured Noom Med in 2026 into 3 tiers: $69/mo branded telehealth (med out-of-pocket), $99-149/mo Microdose GLP-1Rx (low-dose + biomarker monitoring), and the Full GLP-1Rx program ($149 intro → $349/mo on 12-week subscription). Coaching app included at every tier.

Visit Noom Med

Feature	MEDVi	Noom Med
Our Score	7.7/10	7.4/10
Starting Price	$299/mo	$99/mo
Medication Type	Both	Both
Insurance Accepted	No	Yes
Best For	Users who want a low entry price with oral and injectable compounded options	Users who want a tiered entry into GLP-1 care — from $99/mo Microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program
Ranking	#22	#28

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Noom Med

Pros

+Tiered 2026 entry — $69/mo branded telehealth tier lets users start with just medication access and the coaching app
+New Microdose GLP-1Rx program ($99-149/mo) — low-dose GLP-1 + biomarker monitoring for sensitive users
+Insurance accepted for qualifying plans — can significantly reduce out-of-pocket costs on brand-name meds
+Industry-leading behavioral coaching app with years of psychology-based weight loss methodology

Cons

−Tiered pricing creates confusion — $69, $99-149, or $149-349 depending on tier
−Full GLP-1Rx program requires 12-week subscription ($149 intro rate applies only for the first few weeks)
−Medication costs on the $69 tier are out-of-pocket — the low tier price is just the platform
−App coaching still requires real engagement — skip-prone users waste the behavioral value

Our Verdict

MEDVi edges out Noom Med with a score of 7.7/10 vs 7.4/10. If budget is your priority, Noom Med starts at $99/mo compared to MEDVi's $299/mo. Noom Med accepts insurance, which can significantly reduce your out-of-pocket costs. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Noom Med if you want: users who want a tiered entry into glp-1 care — from $99/mo microdose all-in (low-dose + biomarkers + coaching) up to a full $349/mo medication + coaching program.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither MEDVi nor Noom Med feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review